OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
+9.36%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.28%
AUM
$377M
AUM Growth
+$377M
(-26%)
Cap. Flow
-$79.5M
Cap. Flow
% of AUM
-21.07%
Top 10 Holdings %
Top 10 Hldgs %
59.98%
Holding
57
New
10
Increased
13
Reduced
12
Closed
14
Top Buys
| 1 |
Protara Therapeutics
TARA
|
$52M |
| 2 |
Eton Pharmaceutcials
ETON
|
$8.9M |
| 3 |
KALA BIO
KALA
|
$7.23M |
| 4 |
MTEM
Molecular Templates, Inc.
MTEM
|
$7.09M |
| 5 |
MYOV
Myovant Sciences Ltd.
MYOV
|
$4.95M |
Top Sells
Sector Composition
| 1 | Healthcare | 87.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Zymeworks
ZYME
$1.07B
| $4.72M | 1.25% |
133,000
-42,000
| -24% | -$1.49M |
|
|
TCDA
27
DELISTED
Tricida, Inc. Common Stock
TCDA
| $4.27M | 1.13% |
194,000
| – | – |
|
28
Catalyst Pharmaceutical
CPRX
$2.42B
| $4.04M | 1.07% |
+1,050,000
| New | +$4.04M |
|
29
Verastem
VSTM
$585M
| $3.87M | 1.02% |
+1,463,900
| New | +$3.87M |
|
30
Dianthus Therapeutics
DNTH
$781M
| $2.73M | 0.72% |
434,712
-15,238
| -3% | -$95.7K |
|
31
Minerva Neurosciences
NERV
$16.8M
| $2.71M | 0.72% |
+450,100
| New | +$2.71M |
|
32
MacroGenics
MGNX
$121M
| $2.46M | 0.65% |
422,300
+221,800
| +111% | +$1.29M |
|
33
Cidara Therapeutics
CDTX
$1.61B
| $2.25M | 0.6% |
+906,056
| New | +$2.25M |
|
|
FLXN
34
DELISTED
Flexion Therapeutics, Inc.
FLXN
| $2.22M | 0.59% |
281,600
-133,900
| -32% | -$1.05M |
|
|
RDUS
35
DELISTED
Radius Health, Inc.
RDUS
| $2.17M | 0.58% |
167,000
-1,000
| -0.6% | -$13K |
|
|
AMRN
36
Amarin Corp
AMRN
$311M
| $1.82M | 0.48% |
455,000
-210,000
| -32% | -$840K |
|
37
KalVista Pharmaceuticals
KALV
$713M
| $1.72M | 0.46% |
+225,000
| New | +$1.72M |
|
|
PRVB
38
DELISTED
Provention Bio, Inc. Common Stock
PRVB
| $1.53M | 0.4% |
+166,000
| New | +$1.53M |
|
39
Cartesian Therapeutics
RNAC
$267M
| $940K | 0.25% |
+390,000
| New | +$940K |
|
40
TELA Bio
TELA
$65.4M
| $633K | 0.17% |
81,000
-94,000
| -54% | -$735K |
|
41
Acadia Pharmaceuticals
ACAD
$4.34B
| $63K | 0.02% |
1,500
-205,000
| -99% | -$8.61M |
|
|
BLRX
42
BioLineRX
BLRX
$15.5M
| $22K | 0.01% |
16,667
| – | – |
|
43
Aquestive Therapeutics
AQST
$478M
| – | – |
-738,500
| Closed | -$4.3M |
|
44
Axogen
AXGN
$718M
| – | – |
-700,000
| Closed | -$12.5M |
|
|
BPMC
45
DELISTED
Blueprint Medicines
BPMC
| – | – |
-100,000
| Closed | -$8M |
|
46
Fennec Pharmaceuticals
FENC
$247M
| – | – |
-12,000
| Closed | -$78K |
|
47
PTC Therapeutics
PTCT
$4.41B
| – | – |
-191,000
| Closed | -$9.17M |
|
48
Quanterix
QTRX
$202M
| – | – |
-132,200
| Closed | -$3.12M |
|
49
Rhythm Pharmaceuticals
RYTM
$6.75B
| – | – |
-110,500
| Closed | -$2.54M |
|
|
ITCI
50
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| – | – |
-406,600
| Closed | -$14M |
|